Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01807286 · ClinicalTrials.gov registry record · Phase 1
Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT01807286: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01807286 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01807286, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of pomalidomide that can be given in combination with melphalan and dexamethasone that can be given to patients with AL amyloidosis. The safety of this drug combination will also be studied. Pomalidomide is designed to change the body's immune system. It may also interfere with the development of tiny blood vessels that help support tumor growth. This may decrease the growth of cancer cells. Melphalan is designed to damage the DNA (genetic material) of cells, which may cause cancer cells to die. Dexamethasone is a corticosteroid that is similar to a natural hormone made by your body. Dexamethasone is often given to Multiple Myeloma (MM) patients in combination with other chemotherapy to treat cancer. Planned Phase I/II Study terminated early during Phase I portion without continuation to Phase II.
Interventions
- DRUG Melphalan
- DRUG Dexamethasone
- BEHAVIORAL Questionnaires
- DRUG Pomalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2014-01 |
| Est. Completion | 2016-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01807286
The ClinicalTrials.gov registry entry for NCT01807286 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Melphalan is the first listed.
NCT01807286 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01807286 about?
NCT01807286 is a clinical study titled "Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis". The goal of this clinical research study is to find the highest tolerable dose of pomalidomide that can be given in combination with melphalan and dexamethasone that can be given to patients with AL amyloidosis. The safety of this drug combination will also be studied. Pomalidomide is designed to c...
What is the current status of trial NCT01807286?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2014-01. Estimated completion is 2016-02.
What interventions are being tested in trial NCT01807286?
The interventions under investigation include: Melphalan (DRUG), Dexamethasone (DRUG), Questionnaires (BEHAVIORAL), Pomalidomide (DRUG).
Who is sponsoring clinical trial NCT01807286?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.